Quantum computing speeds up drug discovery for potential cancer treatment
Live Forever Club - 27-Jan-2025Traditional methods take years, but this new approach is much quicker
Insilico Medicine
Biotechnology company that uses artificial intelligence to develop new drugs and for aging research
Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
Insilico Medicine Leadership
- Alex Zhavoronkov, PhD, Chairman of the Board, Executive Director & CEO
- Feng Ren, PhD, Executive Director, Co-CEO, Chief Scientific Officer
- Alex Aliper, President
- Michelle Chen, Chief Business Officer
- Sujata Rao, Chief Medical Officer
Insilico Medicine Scientific Advisory Board
- Charles Cantor
- Michael Levitt
- Kai-Fu Lee
- Alán Aspuru-Guzik
- Donald Small
- Klaus Witte
- Stevan Djuric
- Bud Mishra
Visit website: https://insilico.com/
Details last updated 09-Apr-2019
Insilico Medicine News
AI-driven breakthrough targets gut repair in IBD
Genetic Engineering & Biotechnology News (GEN) - 11-Dec-2024How Insilico Medicine’s innovative drug ISM5411 could transform inflammatory bowel disease treatment
AI-developed drug improves lung function in idiopathic pulmonary fibrosis
FierceBiotech - 12-Nov-2024Drug improved chronic cough symptoms, contributing to a better quality of life\
Insilico's AI-designed drug proves effective in treating lung disease
Longevity Technology - 20-Sep-2024Phase 2a trial results show positive outcomes among pulmonary fibrosis patients
Insilico Medicine showcases 10 years of AI success in drug discovery
GEN - 01-Aug-2024AI could cut preclinical drug development time by half, but rigorous trials are crucial
Display all news
Mentioned in this Resource
Alex Zhavoronkov
CEO of InSilico Medicine & Deep Longevity. CSO of Biogerontology Research Foundation
Bud Mishra
Computer scientist and professor at the Courant Institute of Mathematical Sciences of New York University
Charles Cantor
Former Chief Scientific Officer at Sequenom and member of Scientific Advisory Board at Insilico Medicine
Kai-Fu Lee
Chairman and CEO at Sinovation Ventures and President at Sinovation Ventures Artificial Intelligence Institute
Insilico Medicine is also referenced in the following:
Alex Zhavoronkov at ARDD2024: Methylation Clocks and AI Life Models as Sources of Therapeutic Target
Alex Zhavoronkov presented methylation clocks and AI models as groundbreaking tools
ARDD 2021 - 8th Aging Research and Drug Discovery Meeting
31-Aug-2021 to 03-Sep-2021
Online event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen chaired by Morten Scheibye-Knudsen, Daniela Bakula and Alex Zhavoronkov, and with many speakers.
Deep Longevity
AI to track the rate of ageing at the molecular, cellular, tissue, organ, system, physiological, and psychological levels
Enabling AI-Guided End-to-End Drug Discovery - Alex Zhavoronkov at Longevity Summit Dublin 2024
Alex Zhavoronkov delivered a keynote on AI-Guided End-to-End Drug Discovery
Generative AI drug discovery breakthrough, with Alex Zhavoronkov
Alex Zhavoronkov discusses a generative AI breakthrough in drug discovery
Pioneering AI drug development, with Alex Zhavoronkov
Alex Zhavoronkov pioneers AI-powered drug development
Other people at Insilico Medicine
Polina Mamoshina
Chief Scientist and Chief Operating Officer at Deep Longevity and Head of Biomarker Development at Insilico Medicine.
